



**T1D Exchange QI Collaborative  
Clinical Leadership Committee Charter**  
Last Updated: February 24, 2020

## **Purpose**

T1D Exchange QI Collaborative ("T1DX-QI") established a Clinical Leadership Committee to provide expert consultation, deliberation, and advice to the Quality Improvement initiatives, including aims, drivers, interventions, practices, measures, and statistical methods to improve processes and clinical outcomes in diabetes care.

## **Structure and Processes**

### **A. Membership**

**See Appendix A for list of current members and site representation**

The Committee will consist of a minimum of six members, with growth anticipated. Member commitment is for two years with the option to renew their term. Members will consist of endocrinologists and subject-matter experts who are actively working for and committed to pediatric, adult, and older adult populations with T1D.

**Members will included:**

1. T1D Exchange Quality Improvement Team
2. Principal Investigators from each clinic in the T1DX-QI

### **B. Meetings**

The Committee will meet at least quarterly. In-person meetings will be scheduled on an ad hoc basis depending on the work flow and member consensus.

### **C. Responsibilities and Duties**

The following functions are expected to be the common recurring activities of the Committee in carrying out its responsibilities. These functions should serve as a guide with the understanding that the Committee may carry out additional functions and set priorities and procedures.

The Committee will help inform the strategic direction, study or intervention design, dissemination design and assist in identifying new opportunities for T1D Exchange and contribute to the understanding, treatment and other solutions effecting type 1 diabetes. The group will set and review priorities; these discussions will result in actionable recommendations for the direction of the T1DX-QI. The Committee advises and supports the identification of external collaborations and potential funding opportunities for T1D Exchange as needed.

To support these activities, **Committee members will:**

- Review IRB and research protocols
- Develop a 2 year publication roadmap
- Review and provide feedback on scientific methods
- Work in collaboration with Clinical Committee to maximize utilization of technology
- Advise on authorship and publication journals



**D. Conflicts of Interest**

The Committee member must abide by T1D Exchange’s conflict of interest policy. They are requested to disclose all financial interests and working relationships with any entity whose financial interests potentially could be affected by the conduct or outcome of T1D Exchange activities; including all relationships that might have a bearing on his/her role or the perception of this role.

**E. Confidentiality**

The Committee members will keep the material reviewed and deliberations of the Committee strictly confidential. If a Committee member has uncertainty about whether an issue or materials should be kept confidential, this should be discussed with the VP, Population Health and Quality Improvement or CEO of T1D Exchange Inc.

**Appendix A, [Proposed] Committee Membership**

Barbara Davis Center - Adults	TBD
Barbara Davis Center - Pediatrics	TBD
Children’s Mercy	TBD
Cincinnati Children’s Hospital	Sarah Corathers
Nationwide Children’s	TBD
Penn Medicine	TBD
Rady Children’s	TBD
Stanford	TBD
SUNY Upstate - Adults	TBD
SUNY Upstate - Pediatrics	TBD
T1D Exchange Quality Improvement Team	Osagie Ebekozen
T1D Exchange Quality Improvement Team	Nudrat Noor
T1D Exchange Patient Parent Advisory Committee	TBD
Texas Children’s	TBD
University of Michigan	TBD
Wayne State University	TBD